TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

Britain to buy 10 million antibody tests from Roche and Abbott

News Desk (Reuters)
London, United Kingdom
Fri, May 22, 2020 Published on May. 22, 2020 Published on 2020-05-22T01:06:00+07:00

Change text size

Gift Premium Articles
to Anyone

Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
This photo taken on March 11, 2020 shows vials displayed during a neutralising antibody test on the Middle Eastern Respiratory Syndrome (MERS) coronavirus at a Bio Safety Level (BSL) 3 laboratory at the International Vaccine Institute (IVI) in Seoul.Britain said on Thursday it had agreed to acquire over 10 million coronavirus antibody tests from Roche and Abbott which would be rolled out to health and care workers from next week. This photo taken on March 11, 2020 shows vials displayed during a neutralising antibody test on the Middle Eastern Respiratory Syndrome (MERS) coronavirus at a Bio Safety Level (BSL) 3 laboratory at the International Vaccine Institute (IVI) in Seoul.Britain said on Thursday it had agreed to acquire over 10 million coronavirus antibody tests from Roche and Abbott which would be rolled out to health and care workers from next week. (AFP/ Ed JONES)

B

ritain said on Thursday it had agreed to acquire over 10 million coronavirus antibody tests from Roche and Abbott which would be rolled out to health and care workers from next week.

Mass antibody testing is being considered by many countries as a way to speed the reopening of economies devastated by lockdowns and to introduce more tailored social distancing measures.

Health minister Matt Hancock said the tests would be first rolled out to staff, patients and residents in health and care settings.

"This is an important milestone, and it represents further progress in our national testing program," he added.

"We're not yet in a position to say that those who test positive in these antibody tests are immune from coronavirus. But as our understanding of the disease improves, the insight these antibody tests provide will be crucial."

The antibody tests - also known as serology tests - show who has been infected, although it is not yet clear whether the presence of antibodies to the new coronavirus, SARS-CoV-2, confers permanent immunity.

Hancock said an antibody surveillance study had found 17% of people in London and around 5% or higher in the rest of the country had tested positive for coronavirus antibodies.

Earlier this month, a spokesman for Prime Minister Boris Johnson said there was the possibility of issuing some kind of certificate based on immunity but that scientists still needed to know more about that subject area.

Hancock also said that Britain would trial a new antigen test - which shows whether people currently have COVID-19, the disease caused by the new coronavirus - that would return results in 20 minutes without needing to be sent to a lab for processing.

"If it works, we'll roll it out as soon as we can," he said. 

 

Your Opinion Matters

Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.

Enter at least 30 characters
0 / 30

Thank You

Thank you for sharing your thoughts. We appreciate your feedback.

Share options

Quickly share this news with your network—keep everyone informed with just a single click!

Change text size options

Customize your reading experience by adjusting the text size to small, medium, or large—find what’s most comfortable for you.

Gift Premium Articles
to Anyone

Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!

Continue in the app

Get the best experience—faster access, exclusive features, and a seamless way to stay updated.